Pending Claims As Of November 14, 2001

1. A pharmaceutical composition comprising:

   a. an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof;

   b. an amount of atorvastatin or a pharmaceutically acceptable salt thereof; and

   c. a pharmaceutically acceptable carrier or diluent.

2. A pharmaceutical composition of claim 1 comprising amlodipine besylate

3. A pharmaceutical composition of claim 2 comprising the hemicalcium salt of atorvastatin.

84. A kit for achieving a therapeutic effect in a mammal comprising:

   a. a therapeutically effective amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent in a first unit dosage form;

   b. a therapeutically effective amount of atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent in a second unit dosage form; and

   c. container means for containing said first and second dosage forms.

85. A kit of claim 84 comprising amlodipine besylate.

86. A kit of claim 85 comprising the hemicalcium salt of atorvastatin.

87. A kit of claim 86 wherein said therapeutic effect is treatment of hypertension and hyperlipidemia.

88. A kit of claim 86 wherein said therapeutic effect is treatment of angina pectoris.

89. A kit of claim 86 wherein said therapeutic effect is management of cardiac risk.

90. A kit of claim 86 wherein said therapeutic effect is treatment of atherosclerosis.

91. A kit of claim 90 wherein said treatment of atherosclerosis slows the progression of atherosclerotic plaques.

92. A kit of claim 91 wherein said progression of atherosclerotic plaques is slowed in coronary arteries.

93. A kit of claim 91 wherein said progression of atherosclerotic plaques is slowed in carotid arteries.

94. A kit of claim 91 wherein said progression of atherosclerotic plaques is slowed in the peripheral arterial system.

95. A kit of claim 90 wherein said treatment of atherosclerosis causes the regression of atherosclerotic plaques.

96. A kit of claim 95 wherein said regression of atherosclerotic plaques occurs in coronary arteries.

97. A kit of claim 95 wherein said regression of atherosclerotic plaques occurs in carotid arteries.

98. A kit of claim 95 wherein said regression of atherosclerotic plaques occurs in the peripheral arterial system.

99. A method for treating a mammal in need of therapeutic treatment comprising administering to said mammal

(a) an amount of a first compound, said first compound being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(b) an amount of a second compound, said second compound being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first compound and said second compound are administered in a single pharmaceutical composition together with a pharmaceutically acceptable carrier or diluent.

100. A method of claim 99 comprising amlodipine besylate.

101. A method of claim 100 comprising the hemicalcium salt of atorvastatin.

106. A method of claim 99 wherein said therapeutic treatment comprises antihypertensive treatment and antihyperlipidemic treatment.

109. A method of claim 99 wherein said therapeutic treatment comprises antianginal treatment.

112. A method of claim 99 wherein said therapeutic treatment comprises cardiac risk management.

115. A method of claim 99 wherein said therapeutic treatment comprises antiatherosclerotic treatment.

118. The pharmaceutical composition of claim 1 comprising the hemicalcium salt of atorvastatin.

119. The kit of claim 84 comprising the hemicalcium salt of atorvastatin.

120. The method of claim 99 comprising the hemicalcium salt of atorvastatin.121. A method for treating a mammal in need of therapy by the joint administration of the active ingredients designated as (a) and (b) below, which comprises administering to said mammal

(1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) an amount of a second active ingredient (b), said second active ingredient (b) being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each administered together with a pharmaceutically acceptable carrier or diluent.

122. A method of claim 121 wherein active ingredient (a) is amlodipine besylate.

123. A method of claim 122 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

124. A method of claim 121 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

125. The method of claim 121 wherein active ingredients (a) and (b) are administered simultaneously.

126. The method of claim 121 wherein active ingredients (a) and (b) are administered sequentially in either order.

127. A method of treating a mammal which has been diagnosed as suffering from a condition or the risk of a condition which would benefit from therapy by the combined administration of the active ingredients designated as (a) and (b) below, and therefore administration of both (a) and (b) has been prescribed, which comprises administering to said mammal so diagnosed and prescribed

(1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) an amount of a second active ingredient (b), said second active ingredient (b) being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each administered together with a pharmaceutically acceptable carrier or diluent.

128. A method of claim 127 wherein active ingredient (a) is amlodipine besylate.

129. A method of claim 128 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

130. A method of claim 127 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

131. The method of claim 127 wherein active ingredients (a) and (b) are administered simultaneously.

132. The method of claim 127 wherein active ingredients (a) and (b) are administered sequentially in either order.

133. A method of treating combined hypertension and hyperlipidemia in a mammal which has been examined for both hypertension and hyperlipidemia conditions by a medical practitioner and diagnosed as in need of therapy for said conditions by the joint administration of the active ingredients designated as (a) and (b) below, which comprises administering to said mammal

(1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) an amount of a second active ingredient (b), said second active ingredient (b) being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each administered together with a pharmaceutically acceptable carrier or diluent.

134. A method of claim 133 wherein active ingredient (a) is amlodipine besylate.

135. A method of claim 134 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

136. A method of claim 133 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

137. The method of claim 133 wherein active ingredients (a) and (b) are administered simultaneously.

138. The method of claim 133 wherein active ingredients (a) and (b) are administered sequentially in either order.

139. A method for preventing or reducing cardiac risk in a mammal which has been examined and diagnosed as having symptoms or risk factors for cardiac disease and in need of combined therapy to manage such risk by the joint administration of the active ingredients designated as (a) and (b) below, which comprises administering to said mammal

(1) a prophylactically effective amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) a prophylactically effective amount of a second active ingredient (b), said second active ingredient (b) being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each administered together with a pharmaceutically acceptable carrier or diluent.

140. A method of claim 139 wherein active ingredient (a) is amlodipine besylate.

141. A method of claim 140 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

142. A method of claim 139 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

143. The method of claim 139 wherein active ingredients (a) and (b) are administered simultaneously.

144. The method of claim 139 wherein active ingredients (a) and (b) are administered sequentially in either order.

145. A method of treating angina in a mammal which has been examined for angina by a medical practitioner and diagnosed as in need of therapy for said angina by the joint administration of the active ingredients designated as (a) and (b) below, which comprises administering to said mammal

(1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) an amount of a second active ingredient (b), said second active ingredient (b) being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each administered together with a pharmaceutically acceptable carrier or diluent.

146. A method of claim 145 wherein active ingredient (a) is amlodipine besylate

147. A method of claim 146 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

148. A method of claim 145 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

149. The method of claim 145 wherein active ingredients (a) and (b) are administered simultaneously.

150. The method of claim 145 wherein active ingredients (a) and (b) are administered sequentially in either order.

151. A method of treating atherosclerosis in a mammal which has been examined for atherosclerosis by a medical practitioner and diagnosed as in need of therapy for said atherosclerosis by the joint administration of the active ingredients designated as (a) and (b) below, which comprises administering to said mammal

(1) an amount of a first active ingredient (a), said first active ingredient (a) being amlodipine or a pharmaceutically acceptable acid addition salt thereof; and

(2) an amount of a second active ingredient (b), said second active ingredient (b) being atorvastatin or a pharmaceutically acceptable salt thereof;

wherein said first active ingredient (a) and said second active ingredient (b) are each administered together with a pharmaceutically acceptable carrier or diluent.

152. A method of claim 151 wherein active ingredient (a) is amlodipine besylate.

153. A method of claim 152 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

154. A method of claim 151 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

155. The method of claim 151 wherein active ingredients (a) and (b) are administered simultaneously.

156. The method of claim 151 wherein active ingredients (a) and (b) are administered sequentially in either order.

157. The method of claim 151 where the treatment results in slowing the progression of atherosclerotic plaques.

158. The method of claim 157 where the progression of atherosclerotic plaques is slowed in coronary arteries.

159. The method of claim 157 where the progression of atherosclerotic plaques is slowed in the carotid arteries.

160. The method of claim 157 wherein the progression of atherosclerotic plaques is slowed in the peripheral arterial system.

161. The method according to claim 151 wherein the treatment results in a regression of atherosclerotic plaque.

162. The method according to claim 161 wherein the regression of atheroscleotic plaques occurs in the coronary arteries.

163. The method according to claim 161 wherein the regression of atheroscleotic plaques occurs in the carotid arteries.

164. The method according to claim 161 wherein the regression of atheroscleotic plaques occurs in the peripheral arterial system.

165. A kit for achieving a therapeutic effect in a mammal which has been prescribed the joint administration of the active ingredients designated as (a) and (b) below, each active ingredient forming a portion of said kit, comprising in association

(1) a therapeutically effective amount of a first active ingredient (a), said first active ingredient being amlodipine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent in a first unit dosage form;

(2) a therapeutically effective amount of a second active ingredient (b), said second active ingredient being atorvastatin or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent in a second unit dosage form; and

(3) directions for the administration of active ingredients (a) and (b) in a manner to achieve the desired therapeutic effect.

166. A kit of claim 165 wherein active ingredient (a) is amlodipine besylate.

167. A kit of claim 166 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

168. A kit of claim 165 wherein active ingredient (b) is the hemicalcium salt of atorvastatin.

169. The kit of claim 165 where the therapeutic effect is antihypertensive and antihyperlipidemic.

170. The kit of claim 165 where the therapeutic effect is antianginal.

171. The kit of claim 165 where the therapeutic effect is cardiac risk management.

172. The kit of claim 165 where the therapeutic effect is antiatherosclerotic.

173. The method of claim 125 where active ingredients (a) and (b) are administered together in a single pharmaceutical composition.

174. The method of claim 121 where the mammal is in need of therapy for combined hypertension and hyperlipidemia.

175. The method of claim 131 where active ingredients (a) and (b) are administered together in a single pharmaceutical composition.

176. The method of claim 127 where the mammal is in need of therapy for combined hypertension and hyperlipidemia.

177. The method of claim 137 where active ingredients (a) and (b) are administered together in a single pharmaceutical composition.

178. The method of claim 133 where the mammal is in need of therapy for combined hypertension and hyperlipidemia.

179. The method of claim 143 where active ingredients (a) and (b) are administered together in a single pharmaceutical composition.

180. The method of claim 139 where the mammal is in need of therapy for combined hypertension and hyperlipidemia.

181. The method of claim 149 where active ingredients (a) and (b) are administered together in a single pharmaceutical composition.

182. The method of claim 145 where the mammal is in need of therapy for combined hypertension and hyperlipidemia.

183. The method of claim 155 where active ingredients (a) and (b) are administered together in a single pharmaceutical composition.

184. The method of claim 151 where the mammal is in need of therapy for combined hypertension and hyperlipidemia.